A Study of AK104 (SC) in Combination With Oxaliplatin and Capecitabine (XELOX) Versus AK104 (IV) in Combination With XELOX in Participants With Unresectable Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT07449780 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07449780
Sponsor: Akeso
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Gastric / Gastroesophageal Junction Adenocarcinoma

Start date: 2026-03-31
Primary completion: 2027-11-17
Enrollment: 422

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.